Dharmsheel Shrivastav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dharmsheel Shrivastav has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Varun Kumar Sharma
Noida International University, Department of Biotechnology and Microbiology, Greater Noida, Uttar Pradesh, India
6 shared publications - Shilpy Singh
Department of Biotechnology and Microbiology, School of Sciences, Noida International University, Noida, India
4 shared publications - Mirza Masroor Ali Beg
Faculty of Medicine Ala‐Too International University Bishkek Kyrgyzstan
3 shared publications Ved Vrat Verma
Department of Biotechnology and Microbiology, School of Sciences, Noida International University, Gautam Budh Nagar
3 shared publicationsAbhishek Awasthi
Department of Biotechnology and Microbiology, School of Sciences, Noida International University, Gautam Budh Nagar
2 shared publicationsPragati Saxena
Department of Biotechnology and Microbiology, School of Sciences, Noida International University, Gautam Budh Nagar
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (5)
From Rhizosphere to Resistance: Microbe‐Plant Interactions in Eco‐Smart Biocontrol
The increasing limitations of chemical pesticides such as environmental pollution, pathogen resistance, and threats to human and ecosystem health have increased the demand for sustainable, biologically based crop protection methods. Eco‐smart biocontrol has emerged as a game‐changing paradigm that uses beneficial microorganisms associated with plants to suppress phytopathogens, boost plant immunity, and make agroecosystems more resilient over time. Moving beyond traditional single‐strain biocontrol, eco‐smart biocontrol integrates multi‐omics discovery, artificial intelligence‐assisted predictive microbiome design, and dynamic rhizosphere ecology. This review brings together ecological, molecular, and technological dimensions of eco‐smart biocontrol, focusing on the rhizosphere as a dynamic hotspot for plant–microbe interactions. We investigate rhizosphere microbiome assembly and demonstrate the preferential recruitment of beneficial bacteria, fungi, actinomycetes, and mycorrhizal symbionts by plant root exudates. Moreover, the review highlights the impact of innovations in multi‐omics techniques (metagenomics, transcriptomics, proteomics, and metabolomics), systems biology, and artificial intelligence on microbial biocontrol agent discovery, functional validation, and predictive design. Examples from cereal crops, legumes, and horticulture crops indicate that the application of beneficial microbial inoculants can significantly lower the burden of pests and diseases, enhance crop productivity, and fit perfectly within an integrated pest management system. Lastly, we critically analyze the main challenges preventing large‐scale adoption, such as inconsistent field performance, limited microbial survival and competitiveness, and comparative regulatory frameworks across global markets. Ultimately, eco‐smart microbial biocontrol combines mechanistic insights with omics‐driven discovery, artificial intelligence (AI)‐ assisted prediction, advanced formulation strategies, and field‐level validation, creating a strong, scalable, and environmentally friendly framework for resilient, low‐input agricultural systems.
- 28 September 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (5)
Open AccessFrom Rhizosphere to Resistance: Microbe‐Plant Interactions in Eco‐Smart Biocontrol
The increasing limitations of chemical pesticides such as environmental pollution, pathogen resistance, and threats to human and ecosystem health have increased the demand for sustainable, biologically based crop protection methods. Eco‐smart biocontrol has emerged as a game‐changing paradigm that uses beneficial microorganisms associated with plants to suppress phytopathogens, boost plant immunity, and make agroecosystems more resilient over time. Moving beyond traditional single‐strain biocontrol, eco‐smart biocontrol integrates multi‐omics discovery, artificial intelligence‐assisted predictive microbiome design, and dynamic rhizosphere ecology. This review brings together ecological, molecular, and technological dimensions of eco‐smart biocontrol, focusing on the rhizosphere as a dynamic hotspot for plant–microbe interactions. We investigate rhizosphere microbiome assembly and demonstrate the preferential recruitment of beneficial bacteria, fungi, actinomycetes, and mycorrhizal symbionts by plant root exudates. Moreover, the review highlights the impact of innovations in multi‐omics techniques (metagenomics, transcriptomics, proteomics, and metabolomics), systems biology, and artificial intelligence on microbial biocontrol agent discovery, functional validation, and predictive design. Examples from cereal crops, legumes, and horticulture crops indicate that the application of beneficial microbial inoculants can significantly lower the burden of pests and diseases, enhance crop productivity, and fit perfectly within an integrated pest management system. Lastly, we critically analyze the main challenges preventing large‐scale adoption, such as inconsistent field performance, limited microbial survival and competitiveness, and comparative regulatory frameworks across global markets. Ultimately, eco‐smart microbial biocontrol combines mechanistic insights with omics‐driven discovery, artificial intelligence (AI)‐ assisted prediction, advanced formulation strategies, and field‐level validation, creating a strong, scalable, and environmentally friendly framework for resilient, low‐input agricultural systems.
- 17 September 2026
- Published by CABI Publishing
- p. 197-242
Exploration of the Unique Microbiomes of Medicinal Plants, Driven by Their Bioactive Secondary Metabolites
- 17 September 2026
- Published by CABI Publishing
- p. 197-242
Exploration of the Unique Microbiomes of Medicinal Plants, Driven by Their Bioactive Secondary Metabolites
- 17 September 2026
- Published by CABI Publishing
- p. 36-64
Exploration of Microbial Diversity in the Internal Tissues of Plants, and Their Interactions with the Plant
- 17 September 2026
- Published by CABI Publishing
- p. 36-64
Exploration of Microbial Diversity in the Internal Tissues of Plants, and Their Interactions with the Plant
- 1 April 2026
- Published by Springer Nature
- p. 179-203
Targeted Nanotheranostics for Selective Drug Delivery in Cancer
- 1 April 2026
- Published by Springer Nature
- p. 179-203
Targeted Nanotheranostics for Selective Drug Delivery in Cancer
- 1 April 2026
- Published by Springer Nature
- p. 149-177
The Role of Multifunctional Theranostics as Nanomedical Materials in Cancer
- 1 April 2026
- Published by Springer Nature
- p. 149-177
The Role of Multifunctional Theranostics as Nanomedical Materials in Cancer
- Open Access
- 3 February 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 117-129
Differential Expression of MALAT1 and HOTAIR lncRNAs in Early and Advanced Stage Breast Cancer Patients: Potential Prognostic Biomarkers
Long non-coding RNAs (lncRNAs) have emerged as key regulators of gene expression involved in tumor initiation, progression, and metastasis. Among them, HOTAIR (HOX Transcript Antisense Intergenic RNA) and MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1) have been implicated in several cancers, including breast cancer. However, their stage-specific expression patterns and prognostic relevance in breast cancer remain underexplored. This study aimed to evaluate the differential expression of HOTAIR and MALAT1 in early-stage (I–II) and late-stage (III–IV) breast cancers and to assess their association with clinicopathological and demographic parameters to determine their potential as prognostic biomarkers. Eighty breast cancer samples were analyzed for HOTAIR and MALAT1 expression using qRT-PCR. Clinicopathological data, including age, menopausal status, lymph node involvement, and hormone receptor status (ER, PR, HER2/neu), were collected. Logistic regression, ROC curve, and univariate analyses assessed their diagnostic and predictive significance. HOTAIR expression was significantly upregulated in late-stage (III–IV) breast cancer compared with early-stage (I–II) cases (p < 0.05), showing strong association with lymph node metastasis, postmenopausal status, and receptor negativity. ROC analysis demonstrated HOTAIR’s predictive potential with an AUC of 0.73 (sensitivity: 64%; specificity: 86%). MALAT1 expression was non-significantly elevated in late-stage tumors. Logistic regression analysis we observed that overexpression of HOTAIR, lymph node involvement, and hormone receptor negativity as increases disease risk. The findings indicate that HOTAIR over expression serves as a potential prognostic biomarker for breast cancer at late stage and associated with clinicopathological features and disease progression.
- 3 February 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 117-129
Open AccessDifferential Expression of MALAT1 and HOTAIR lncRNAs in Early and Advanced Stage Breast Cancer Patients: Potential Prognostic Biomarkers
Long non-coding RNAs (lncRNAs) have emerged as key regulators of gene expression involved in tumor initiation, progression, and metastasis. Among them, HOTAIR (HOX Transcript Antisense Intergenic RNA) and MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1) have been implicated in several cancers, including breast cancer. However, their stage-specific expression patterns and prognostic relevance in breast cancer remain underexplored. This study aimed to evaluate the differential expression of HOTAIR and MALAT1 in early-stage (I–II) and late-stage (III–IV) breast cancers and to assess their association with clinicopathological and demographic parameters to determine their potential as prognostic biomarkers. Eighty breast cancer samples were analyzed for HOTAIR and MALAT1 expression using qRT-PCR. Clinicopathological data, including age, menopausal status, lymph node involvement, and hormone receptor status (ER, PR, HER2/neu), were collected. Logistic regression, ROC curve, and univariate analyses assessed their diagnostic and predictive significance. HOTAIR expression was significantly upregulated in late-stage (III–IV) breast cancer compared with early-stage (I–II) cases (p < 0.05), showing strong association with lymph node metastasis, postmenopausal status, and receptor negativity. ROC analysis demonstrated HOTAIR’s predictive potential with an AUC of 0.73 (sensitivity: 64%; specificity: 86%). MALAT1 expression was non-significantly elevated in late-stage tumors. Logistic regression analysis we observed that overexpression of HOTAIR, lymph node involvement, and hormone receptor negativity as increases disease risk. The findings indicate that HOTAIR over expression serves as a potential prognostic biomarker for breast cancer at late stage and associated with clinicopathological features and disease progression.
- 21 November 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Machine Learning-Driven Stratification of Post-COVID Blood Pressure Risk: A Decision Tree Approach Focused on Age
The COVID-19 pandemic has led to a surge in long-term cardiovascular complications, including abnormal blood pressure (BP) profiles in recovered individuals. This study investigates the feasibility of using a Decision Tree classifier to predict post-COVID blood pressure status (high vs. low) among married individuals based solely on age. A dataset of $\mathbf{1 5 0}$ post- COVID patients was filtered to include only married individuals, with age as the sole predictive feature. This dataset comprised married adults aged 25-75 years who had previously been hospitalized with moderate to severe COVID-19. The target variable was categorized into high and low BP based on a $130 / 80 ~\text{mm} \text{Hg}$ threshold. The model, developed in Python using scikit-learn, achieved 87.5% accuracy with high precision for identifying high BP cases but exhibited reduced sensitivity for low blood pressure cases (precision: $\mathbf{0. 8 8}$; recall: $\mathbf{1. 0 0}$; AUC: $\mathbf{0. 8 9}$). However, the model exhibited reduced sensitivity for low blood pressure cases, which warrants further model refinement. The decision tree revealed age-based risk stratification, suggesting increasing age is associated with elevated post- COVID BP. Despite its limitations, including reliance on a single feature, the model provides an initial example of how interpretable machine learning tools may assist early cardiovascular risk screening in post-COVID care. Future work should incorporate additional demographic and clinical variables to improve predictive accuracy and generalizability.- 21 November 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-6
Machine Learning-Driven Stratification of Post-COVID Blood Pressure Risk: A Decision Tree Approach Focused on Age
The COVID-19 pandemic has led to a surge in long-term cardiovascular complications, including abnormal blood pressure (BP) profiles in recovered individuals. This study investigates the feasibility of using a Decision Tree classifier to predict post-COVID blood pressure status (high vs. low) among married individuals based solely on age. A dataset of $\mathbf{1 5 0}$ post- COVID patients was filtered to include only married individuals, with age as the sole predictive feature. This dataset comprised married adults aged 25-75 years who had previously been hospitalized with moderate to severe COVID-19. The target variable was categorized into high and low BP based on a $130 / 80 ~\text{mm} \text{Hg}$ threshold. The model, developed in Python using scikit-learn, achieved 87.5% accuracy with high precision for identifying high BP cases but exhibited reduced sensitivity for low blood pressure cases (precision: $\mathbf{0. 8 8}$; recall: $\mathbf{1. 0 0}$; AUC: $\mathbf{0. 8 9}$). However, the model exhibited reduced sensitivity for low blood pressure cases, which warrants further model refinement. The decision tree revealed age-based risk stratification, suggesting increasing age is associated with elevated post- COVID BP. Despite its limitations, including reliance on a single feature, the model provides an initial example of how interpretable machine learning tools may assist early cardiovascular risk screening in post-COVID care. Future work should incorporate additional demographic and clinical variables to improve predictive accuracy and generalizability.- 2 May 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 13 (21) , 10507-10528
Comprehensive survey of plasmonic nano-dendrites: from fabrication to surface-enhanced Raman scattering (SERS) applications
Fabrication methods and SERS applications of plasmonic dendrites.
- 2 May 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 13 (21) , 10507-10528
Comprehensive survey of plasmonic nano-dendrites: from fabrication to surface-enhanced Raman scattering (SERS) applications
Fabrication methods and SERS applications of plasmonic dendrites.
- Open Access
- 31 December 2024
- Published by Salud, Ciencia y Tecnologia in Seminars in Medical Writing and Education
- Vol. 3, 513
Integrating Natural Language Processing in Medical Information Science for Clinical Text Analysis
The rapid digitization of healthcare data has led to an exponential increase in unstructured clinical text, necessitating the integration of Natural Language Processing (NLP) in Medical Information Science. This research explores deep learning-based NLP techniques for clinical text analysis, focusing on Named Entity Recognition (NER), disease classification, adverse drug reaction detection, and clinical text summarization. The study leverages state-of-the-art transformer models such as BioBERT, ClinicalBERT, and GPT-4 Medical, which demonstrate superior performance in extracting key medical entities, classifying diseases, and summarizing electronic health records (EHRs). Experimental results on benchmark datasets such as MIMIC-III, i2b2, and ClinicalTrials.gov show that ClinicalBERT outperforms traditional ML models by achieving an F1-score of 89.9% in NER tasks, while GPT-4 Medical improves EHR summarization efficiency by 40%. By means of automated medical documentation, clinical decision support, and real-time adverse drug event detection which integrates NLP into healthcare systems diagnostic accuracy, physician efficiency, and patient safety are much improved. NLP-driven medical text analysis has great potential to transform clinical procedures and raise patient outcomes despite obstacles like computing costs, data privacy issues, and model interpretability. Improving domain-specific AI models, maximising real-time processing, and guaranteeing ethical AI deployment in healthcare should be the key priorities of next studies.
- 31 December 2024
- Published by Salud, Ciencia y Tecnologia in Seminars in Medical Writing and Education
- Vol. 3, 513
Open AccessIntegrating Natural Language Processing in Medical Information Science for Clinical Text Analysis
The rapid digitization of healthcare data has led to an exponential increase in unstructured clinical text, necessitating the integration of Natural Language Processing (NLP) in Medical Information Science. This research explores deep learning-based NLP techniques for clinical text analysis, focusing on Named Entity Recognition (NER), disease classification, adverse drug reaction detection, and clinical text summarization. The study leverages state-of-the-art transformer models such as BioBERT, ClinicalBERT, and GPT-4 Medical, which demonstrate superior performance in extracting key medical entities, classifying diseases, and summarizing electronic health records (EHRs). Experimental results on benchmark datasets such as MIMIC-III, i2b2, and ClinicalTrials.gov show that ClinicalBERT outperforms traditional ML models by achieving an F1-score of 89.9% in NER tasks, while GPT-4 Medical improves EHR summarization efficiency by 40%. By means of automated medical documentation, clinical decision support, and real-time adverse drug event detection which integrates NLP into healthcare systems diagnostic accuracy, physician efficiency, and patient safety are much improved. NLP-driven medical text analysis has great potential to transform clinical procedures and raise patient outcomes despite obstacles like computing costs, data privacy issues, and model interpretability. Improving domain-specific AI models, maximising real-time processing, and guaranteeing ethical AI deployment in healthcare should be the key priorities of next studies.
- Open Access
- 31 December 2024
- Published by Salud, Ciencia y Tecnologia in Seminars in Medical Writing and Education
- Vol. 3, 521
Bioelectronic Medicine and Neural Interfaces for Treating Neurological Disorders in Biomedical Engineering
Neurological diseases can be treated in a whole new way with bioelectronic medicine, which uses neural connections to directly communicate with the nervous system. This field blends neuroscience, engineering, and clinical practice to make gadgets that can change nerve activity with a level of accuracy that has never been seen before. Recent progress in biomedical engineering has made it possible to create very complex neural connections that can record and trigger activity in neurones at the very small scale. For many neurological conditions, like Parkinson's disease, epilepsy, and chronic pain, these gadgets show promise as new ways to treat them. Traditionally, these conditions have been hard to control with medicine alone. Electrical activation of nerves to repair or change brain function is what bioelectronic medicine is all about. One example is vagus nerve stimulation (VNS), which has become a useful way to help people with refractory epilepsy and depression. This shows that neural interfaces can have big practical effects. Deep brain stimulation (DBS), which uses electrical signals to target specific parts of the brain, has also made a huge difference in the movement ability of people with Parkinson's disease. Adding bioelectronics to real-time data analytics and machine learning methods is also making it possible for treatments that can change based on the brain state of the patient? This personalized method not only makes treatments work better but also cuts down on side effects, which is a big change from the old way of doing things where one answer fits all. Biocompatibility of implanted devices, long-term security of neural interfaces, and ethical concerns about device placement and brain editing are some of the problems that this field is facing as it changes quickly. These problems are still being studied and tested in humans, with the goal of creating better, more successful, and less invasive solutions.
- 31 December 2024
- Published by Salud, Ciencia y Tecnologia in Seminars in Medical Writing and Education
- Vol. 3, 521
Open AccessBioelectronic Medicine and Neural Interfaces for Treating Neurological Disorders in Biomedical Engineering
Neurological diseases can be treated in a whole new way with bioelectronic medicine, which uses neural connections to directly communicate with the nervous system. This field blends neuroscience, engineering, and clinical practice to make gadgets that can change nerve activity with a level of accuracy that has never been seen before. Recent progress in biomedical engineering has made it possible to create very complex neural connections that can record and trigger activity in neurones at the very small scale. For many neurological conditions, like Parkinson's disease, epilepsy, and chronic pain, these gadgets show promise as new ways to treat them. Traditionally, these conditions have been hard to control with medicine alone. Electrical activation of nerves to repair or change brain function is what bioelectronic medicine is all about. One example is vagus nerve stimulation (VNS), which has become a useful way to help people with refractory epilepsy and depression. This shows that neural interfaces can have big practical effects. Deep brain stimulation (DBS), which uses electrical signals to target specific parts of the brain, has also made a huge difference in the movement ability of people with Parkinson's disease. Adding bioelectronics to real-time data analytics and machine learning methods is also making it possible for treatments that can change based on the brain state of the patient? This personalized method not only makes treatments work better but also cuts down on side effects, which is a big change from the old way of doing things where one answer fits all. Biocompatibility of implanted devices, long-term security of neural interfaces, and ethical concerns about device placement and brain editing are some of the problems that this field is facing as it changes quickly. These problems are still being studied and tested in humans, with the goal of creating better, more successful, and less invasive solutions.